Section 2 - iodine equivalent added
Section 4.2 - IV urography – adults -deletion of examples obesity or impaired renal function after the text “It may be necessary to increase the dose in individual cases”. Whole body CT -deletion of the text “ Infusion is preferable for slow scanners and injection for fast scanners”
Section 4.3 - deletion of “Hysterosalpingography must not be carried out during pregnancy or in patients with acute inflammatory conditions in the pelvic cavity”. This text has been moved to section 4.4.
Section 4.4 - the text has been extensively revised and re-formatted under the following headings :Hypersensitivity reactions; Thyroid dysfunction; Cerebral arteriosclerosis, pulmonary emphysema or poor general health; Renal impairment; Hydration; Cardiovascular disease; CNS disorders; Thromboembolic events; Phaeochromocytoma; Anxiety; Myelography; Hysterosalpingography.
Section 4.5 - addition of the heading “Biguanides (metformin) to the paragraph relating to diabetic nephropathy.
Deletion of “Hypersensitivity reactions can be aggravated in patients on beta-blockers”
Insertion of “ Beta-blockers: Patients who experience hypersensitivity reactions while taking beta-blockers may be resistant to treatment effects of beta agonists (see section 4.4)”
Insertion of new heading “Interleukin:”
Insertion of “Radioisotopes: If iodine isotopes are to be administered for the diagnosis of thyroid disease, it should be borne in mind that after the administration of iodinated contrast media which are excreted via the kidneys, the capacity of the thyroid tissue to take up iodine will be reduced for 2 weeks and sometimes up to 6 weeks.” (moved from section 4.5)
Section 4.8 - the section has been extensively revised and the side effects presented in a table with associated frequencies. Information given on the basis for frequency estimates.
Section 4.9 - deletion of “Acute symptoms of poisoning are unlikely with intravascular administration. In special cases … and electrolytes should be adjusted” Insertion of new text “ Symptoms may include fluid and electrolyte imbalance, renal failure, cardiovascular and pulmonary complications. Monitor fluids, electrolytes and renal function. Treatment of overdose should be directed towards the support of vital functions. Ultravist is dialyzable”.
Section 5.1 - addition of a table listing the physico-chemical characteristics of the Ultravist range.
Section 10 - date of revision of text revised to 8 August 2006
|
